Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Laura C CoatesIain B McInnesJoseph F MerolaRichard B WarrenArthur KavanaughAlice B GottliebLaure GossecDeepak AssudaniRajan BajracharyaJason CoarseBarbara InkChristopher T RitchlinPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
The safety profile of bimekizumab was consistent with previous reports, with no new safety signals identified. Sustained joint and efficacy responses were observed over 3 years.